Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists

US9982029B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Martin Bossart · Frankfurt am Main, DE
• Andreas Evers · Frankfurt am Main, DE
• Torsten Haack · Frankfurt am Main, DE
• Katrin Lorenz · Frankfurt am Main, DE
• Dieter Kadereit · Kelkheim, DE
• Michael Wagner · Frankfurt am Main, DE
• Bernd Henkel · Frankfurt am Main, DE

Key dates

• Filing date: Jul 8, 2016
• Grant date: May 29, 2018
• Expiry date: Jul 8, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.